Poteligeo®
Understanding Poteligeo®
Poteligeo® (mogamulizumab-kpkc) is a prescription medicine indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.
Poteligeo® is a CC chemokine receptor type 4 (CCR4)-directed monoclonal antibody administered by intravenous infusion. Mogamulizumab-kpkc is a defucosylated, humanized IgG1 kappa monoclonal antibody.
How Poteligeo® Works:
- Targets CCR4: Poteligeo® contains mogamulizumab-kpkc, a CCR4-directed monoclonal antibody that binds to the CC chemokine receptor type 4 (CCR4).
- Enhances antibody-dependent cellular cytotoxicity (ADCC): In nonclinical studies, binding of mogamulizumab-kpkc to CCR4 enhanced ADCC against CCR4-expressing target cells.
FDA Approval:
Poteligeo® (mogamulizumab-kpkc) received its initial U.S. FDA approval in 2018 for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.
For more information, please visit the Poteligeo® patient website. Speak with your healthcare provider to determine if Poteligeo® is the right treatment option for you.
Referral Form: |
WHAT IT TREATS: |
MANUFACTURER: Kyowa Kirin, Inc.
|
CLASS: CC chemokine receptor type 4 (CCR4)-directed monoclonal antibody |
|
PRESCRIBED BY:
|
|
HOW ADMINISTERED: Intravenous (IV) infusion |
|
FREQUENCY: Weekly during the first 28-day cycle, then every 2 weeks thereafter |
Length of infusion: At least 60 minutes |
FOR MORE INFORMATION: |
Related drugs
